New Triple-Drug cocktail targets tough pancreatic cancer
NCT ID NCT07348107
First seen Jan 18, 2026 · Last updated May 10, 2026 · Updated 20 times
Summary
This early-stage study tests whether adding three drugs—ATRA, SDK002 (arsenic trioxide), and tislelizumab—to standard chemotherapy is safe for people with advanced pancreatic cancer that has spread or can't be removed. Ten participants will receive all treatments together, and researchers will monitor side effects and see if the combination helps them live longer. The goal is to find a safer, more effective way to control this aggressive cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED PANCREATIC DUCTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Verspeeten Family Cancer Centre
London, Ontario, N6A 5W9, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.